Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1060965

registered interest
date	14/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Counselling
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the Government has to ensure that people with cancer are able to access psychological and emotional support.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	909320
answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>By 2021, every person diagnosed with cancer will have access, where appropriate, to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. The needs assessment guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns, including psychological and emotional.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/02/2019 17:25:31 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

1050100

registered interest
date	28/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 March 2018 to Question 134294 on Haematological Cancer, when he plans for the evaluation of the rapid diagnostic centres to be published; and he plans for that evaluation to inform the national roll-out of the centres as proposed in the NHS Long-Term Plan.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	213321
answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Ten multi-disciplinary diagnostic centres are being piloted through the Accelerate, Co-ordinate, Evaluate (ACE) partnership between Cancer Research UK, Macmillan Cancer Support and NHS England. This pilot programme will end in March 2019. Early findings from those sites informed the plans for roll out of the Rapid Diagnostic Centres as part of the NHS Long Term Plan.</p><p> </p><p>During 2019/20, the ACE Programme will share further evaluation from the pilot centres. The findings will continue to inform plans for expansion of the Rapid Diagnostic Centres, alongside work being led by Cancer Alliances to improve early diagnosis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:31:33 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

1050101

registered interest
date	28/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asparaginase
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207238 on Asparaginase, what steps Porton Biopharma will take to increase capacity of erwinase and better supply the (a) UK and (b) world market for the remainder of 2019.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	213322
answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase capacity and supply in both the short and long term. These include the following:</p><p>- Extending operational activities to 24 hours a day, seven days a week to maximise fermentation of the product;</p><p>- Implementing an ongoing capital programme including construction of a new pharmaceutical fermentation facility. The facility was completed in April 2018 and is currently undergoing testing; it has an increased capacity fermentation suite which will enable PBL to manufacture at larger scale and is due to start producing product Q3 2019 for regulatory approval to market;</p><p>- A new filling and freeze-drying building was completed in February 2016. The installation of a new filling line which covers the entire process, including vial washing, filling, stoppering and freeze drying. The new line has been designed with systems which monitor all critical parameters throughout the process to accelerate batch release and will accommodate increased capacity. The beneficial use of this and the fermentation facility will coincide to maximise increased product output; and</p><p>- Sourcing replacement suppliers, including for new stoppers and new vials for the product, ensuring that maximum batch sizes can be achieved with minimal product rejects. This programme is complete.</p><p> </p><p>PBL has made significant investments into increasing product capacity and will continue to release future batches as soon as they become available to Jazz Pharmaceuticals (who are responsible for the packaging/distribution and allocation of worldwide product supply).</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:09:48 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

1039028

registered interest
date	10/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asparaginase
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	207238
answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.</p><p> </p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.</p><p> </p><p>The Department and PHE will continue to monitor the situation closely.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2019 12:18:00 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

1017502

registered interest
date	30/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of (a) leukaemia, (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma and (d) myeloma cases were diagnosed at each cancer stage in each of the last five years.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	197620
answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>This information is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/12/2018 15:38:39 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith